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Guidelines and medication
compliance
To the Editor: ‘A clinical update from Kidney Disease:
Improving Global Outcomes (KDIGO)’ was reported by
Herzog CA et al.1 emphasizing the control of serum calcium
and phosphate concentrations in reducing vascular calci-
ﬁcation. Despite the availability of guidelines, medication
compliance may not be optimal (sometimes because of
inadequate instructions given to patients).
We report on a 42-year-old hemodialysis patient admit-
ted to our hospital for renal transplantation evaluation.
Plain radiography of the abdomen showed disk-shaped
pieces of high-density foreign material (Figure 1a). On
reviewing his medications, it was found that lanthanum
carbonate (1500mg daily) was being used as an oral
phosphate binder, and the radiological ﬁndings reﬂected
intact tablets in the gut. These tablets should be chewed so
that lanthanum carbonate dissociates in the upper gastro-
intestinal tract to give lanthanum ions (La3þ ) that bind
with phosphate. After proper instructions on how to
take this medication, his phosphate level decreased from
7.0 to 6.0mg/dl. Plain radiography of the abdomen showed
that the size of lanthanum carbonate tablets had been
appropriately reduced (Figure 1b). Not achieving clinical
guideline benchmarks may sometimes simply reﬂect inade-
quate instruction given to patients on how to take
medications.
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Have we observed the
implications of the acute fall
in eGFR during treatment
with losartan?
To the Editor: Holtkamp et al.1 recently reported a slower
decline in renal function after an initial decrease in estimated
glomerular ﬁltration rate (eGFR) in patients assigned to angio-
tensin receptor blockers (ARBs). This was interpreted to indicate
a favorable response, and thus ARBs should be continued with
various precautions. From Table 3, however, a very robust
increase in probability of reaching study end point as a function
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Figure 1 |Abdominal plain film showed diffuse radiopaque material. (a) Abdominal plain film showed disk-shaped pieces of
high-density material. After improvement of adherence to this medication, his phosphate level decreased from 7.0 to 6.0mg/dl. (b) Plain
radiography of the abdomen showed that the lanthanum carbonate tablets had been chewed to pieces.
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